Cost and utilization impact of a clinical pathway for patients undergoing pancreaticoduodenectomy

被引:162
|
作者
Porter, GA [1 ]
Pisters, PWT [1 ]
Mansyur, C [1 ]
Bisanz, A [1 ]
Reyna, K [1 ]
Stanford, P [1 ]
Lee, JE [1 ]
Evans, DB [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
关键词
pancreaticoduodenectomy; costs; clinical pathway; resource utilization;
D O I
10.1007/s10434-000-0484-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background:When implemented in several common surgical procedures, clinical pathways have been reported to reduce costs and resource utilization, while maintaining or improving patient care. However, then is little data to support their use in more complex surgery. The objective of this study was to determine the effects of clinical pathway implementation in patients undergoing elective pancreaticoduodenectomy (PD) on cost and resource utilization. Methods: Outcome data from before and after the development of a clinical pathway were analyzed. The clinical pathway standardized the preoperative outpatient care, critical care, and postoperative floor care of patients who underwent PD. An independent department determined total costs for each patient, which included all hospital and physician costs, in a blinded review. Outcomes that were examined included perioperative mortality, postoperative morbidity, length of stay, readmissions, and postoperative clinic visits. Results: From January, 1996 to December, 1998, 148 consecutive patients underwent PD or total pancreatectomy; 68 before pathway development (PrePath) and 80 after pathway implementation (PostPath). There were no significant differences in patient demographics, comorbid conditions, underlying diagnosis, or use of neoadjuvant therapy between the two groups. Mean total costs were significantly reduced in PostPath patients compared with PrePath patients ($36,627 vs. $47,515; P = .003). Similarly, mean length of hospital stay was also significantly reduced in PostPath patients (13.5 vs. 16.4 days; P = .001). The total cost differences could not be attributed solely to differences in room and board costs. Cost and length-of-stay differences remained when outliers were excluded from the analysis. Despite these findings, there were no significant differences between PrePath and PostPath patients in terms of perioperative mortality (3% vs, 1%), readmissions within 1 month of discharge (15% vs. 11%), or mean number of clinic visits within 90 days of discharge (3.3 vs. 3.3 visits). Conclusions: The establishment of a clinical pathway for PD patients dramatically reduced costs and resource utilization without any apparent detrimental effect on quality of patient care. These findings support the implementation of clinical pathways for PD patients, as well as investigation into pathway care for other complex surgical procedures.
引用
收藏
页码:484 / 489
页数:6
相关论文
共 50 条
  • [41] Beneficial impact of a clinical care pathway in patients with testicular cancer undergoing retroperitoneal lymph node dissection
    Chang, SS
    Smith, JA
    Girasole, C
    Baumgartner, RG
    Roth, BJ
    Cookson, MS
    JOURNAL OF UROLOGY, 2002, 168 (01): : 87 - 92
  • [42] Impact of Weight Loss on Surgical Outcomes in Resectable Pancreatic Cancer Patients Undergoing Pancreaticoduodenectomy (PD)
    Emerenziani, Sara
    Valeri, Sergio
    Muscaritoli, Maurizio
    Guarino, Michele Pier Luca
    Molfino, Alessio
    Cocca, Silvia
    Rescio, Maria Paola
    Asensio, Laura Maria Trillo
    Lucia, Simone
    Cicala, Michele
    Coppola, Roberto
    GASTROENTEROLOGY, 2016, 150 (04) : S319 - S319
  • [43] The impact of the muscle mass-to-fat ratio on the prognosis of patients undergoing pancreaticoduodenectomy for pancreatic cancer
    Xu, Long-Jie
    Zhang, Sheng-Qiang
    Cao, Chun
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2025, 41 (02):
  • [44] Impact of comorbidity on hospitalization cost in patients undergoing radical prostatectomy
    Obirieze, Augustine
    Haider, Adil H.
    Cornwell, Edward E., III
    Ahaghotu, Chiledum
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2012, 215 (03) : S142 - S142
  • [45] COPD Exacerbation: Impact of Clinical Pathway for Clinical Outcomes and Cost Control in Bogor
    Kosasih, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [46] Prehabilitation in patients undergoing pancreaticoduodenectomy: a randomized controlled trial
    Ausania, Fabio
    Senra, Paula
    Melendez, Reyes
    Caballeiro, Regina
    Ouvina, Ruben
    Casal-Nunez, Enrique
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2019, 111 (08) : 603 - 608
  • [47] Predictive factors of late cholangitis in patients undergoing pancreaticoduodenectomy
    Yasuhiro Ito
    Yuta Abe
    Minoru Kitago
    Osamu Itano
    Yuko Kitagawa
    World Journal of Surgical Oncology, 16
  • [48] Incidence and Management of Arterial Anomalies in Patients Undergoing Pancreaticoduodenectomy
    Perwaiz, Azhar
    Singh, Amanjeet
    Singh, Tanveer
    Chaudhary, Adarsh
    JOURNAL OF THE PANCREAS, 2010, 11 (01): : 25 - 30
  • [49] Establishing standards of quality for elderly patients undergoing pancreaticoduodenectomy
    Pratt, Wande
    Vanounou, Tsafrir
    Maithel, Shishir
    Vollmer, Charles M.
    Callery, Mark P.
    GASTROENTEROLOGY, 2006, 130 (04) : A887 - A887
  • [50] The importance of assessing the SMA margin in patients undergoing pancreaticoduodenectomy
    Cho, Edward Eun
    Osman, Houssam
    Dietemann, Daniel
    Jeyarajah, Rohan
    INTERNATIONAL JOURNAL OF HEPATOBILIARY AND PANCREATIC DISEASES, 2019, 9